Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 4, 2012, Pages 515-525

  Younk, Lisa M ^a   Davis, Stephen N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid sequestrant; Cholesterol; Colesevelam; Glucose; Glycemic control; Lipid control; Low density lipoprotein cholesterol; Type 2 diabetes mellitus

Indexed keywords

COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ESTRADIOL; ESTROGEN; EZETIMIBE; FARNESOID X RECEPTOR; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADJUVANT THERAPY; BLOATING; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEARTBURN; HORMONE RELEASE; HUMAN; HYPERCHOLESTEROLEMIA; LICENCE; LONG TERM CARE; MEDICAL RECORD REVIEW; MEDLINE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH PARESIS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VASCULAR DISEASE; WEIGHT GAIN;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CHOLAGOGUES AND CHOLERETICS; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG INTERACTIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84858803656     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.672973     Document Type: Review

References (72)

1. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
2. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
4. Kennedy AG, MacLean CD, Littenberg B, et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005;28:1029-34
5. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22
6. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83
7. Suzuki T, Oba K, Igari Y, et al. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: An open-label, randomized, case-control, crossover study. J Diabetes Complications 2012;published online 10 January 2012; doi:10.1016/j.jdiacomp.2011.11.008
8. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74 . This long-term clinical outcome study demonstrated that treatment with a BAS reduced the risk of primary coronary heart disease in association with reductions in LDL-C and total cholesterol.
9. Staels B, Handelsman Y, Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep 2010;10:70-7
10. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64
11. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900
12. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch Intern Med 2008;168:1975-83 This clinical trial demonstrated improvements in glycemic control and LDL-C in type 2 diabetes when colesevelam was added to existing metformin therapy.
13. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84 Results from this study showed that colesevelam induces reduced LDL-C levels and additional improvements in glycemic control when added to sulfonylurea therapy.
14. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40 In this study, LDL-C and glycemic control were improved during colesevelam therapy in patients treated concurrently with insulin-based therapy.
15. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74
16. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517-26
17. Li T, Chiang JY. Bile acid signaling in liver metabolism and diseases. J Lipids 2012;published online 3 October 2011; doi:10.1155/2012/754067
18. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-25
19. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study. Diabetologia 2012;55:432-42 . This study showed that colesevelam therapy enhanced GLP-1 and GIP secretion, providing a potential link between BA sequestration and improved glycemic control.
20. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010;52:1455-64
21. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J 2006;99:257-73
22. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: A pooled analysis. Metab Syndr Relat Disord 2009;7:255-8
23. Rigby SP, Handelsman Y, Lai YL, et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63
24. Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm 2002;59:932-9
25. Herrema H, Meissner M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 2010;51:806-16
26. Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int 2010;4:741-8
27. Aldridge MA, Ito MK. Colesevelam hydrochloride: A novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907
28. Brunetti L, Hermes-Desantis ER. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother 2010;44:1196-206
29. Daily Med: WELCHOL (colesevelam hydrochloride) tablet, film coated; WELCHOL (colesevelam hydrochloride) for suspension. Daiichi Sankyo, Inc. Bethesda, MD: U.S. National Library of Medicine, 2011. Available from: Http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=4a06d3b2-7229-4398-baba- 5d0a72f63821 [Last accessed 7 December 2011]
30. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009;16:1-9
31. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin Proc 2001; 76:971-8232
32. Heller DP, Burke SK, Davidson DM, Donovan JM. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother 2002;36:398-403
33. Rosenbaum DP, Petersen JS, Ducharme S, et al. Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. J Pharm Sci 1997;86:591-5
34. Weitzman SP, Ginsburg KC, Carlson HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid 2009;19:77-9
35. Brown KS, Armstrong IC, Wang A, et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharmacol 2010;50:554-65
36. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-50
37. Donovan JM, Kisicki JC, Stiles MR, et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002;36:392-7
38. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: A new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008;24:995-1009
39. Moore A, Phan BA, Challendar C, et al. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol 2007;1:620-5
40. Daily Med: ZETIA (ezetimibe) tablet. MSP Distribution Services - LLC. Bethesda, MD: U.S. National Library of Medicine, 2012. Available from: Http://dailymed.nlm.nih.gov/dailymed/lookup. cfm?setid=a773b0b2-d31c-4ff4-b9e8- 1eb2d3a4d62a [Last accessed 15 February 2012]
41. Daily Med: NIASPAN ER (niacin) tablet, film coated, extended release. Lake Erie Medical DBA Quality Care Products LLC. Bethesda, MD: U.S. National Library of Medicine, 2011. Available from: Http://dailymed.nlm.nih. gov/dailymed/lookup.cfm? setid=0dfe662a-f2ac-4f10-9a08- 54cbd0c6dec6 [Last accessed 15 February 2012]
42. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14:681-90
43. Walker JR, Brown K, Rohatagi S, et al. Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). J Clin Pharmacol 2009;49:1185-95
44. Hanus M, Zhorov E. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J Pharm Sci 2006;95:2751-9
45. Goldfine AB, Fonseca VA, Jones MR, et al. Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes. Horm Metab Res 2010;42:23-30
46. Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: Efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010;156:231-6
47. Ovalle F, Philis-Tsimikas A, Truitt K, et al. Colesevelam HCl improves glycemic control, independent of age, in patients with type 2 diabetes uncontrolled on metformin, sulfonylurea, or insulin-based therapy. Diabetes 2007;56(Suppl 1):A536
48. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 2009;204:342-4
49. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
50. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-64
51. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-7
52. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 2009;32:1924-9
53. Baker WL, Talati R, White CM, Coleman CI. Differing effects of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
54. Davidson MH. Combination therapy for dyslipidemia: Safety and regulatory considerations. Am J Cardiol 2002;90(Suppl 2):50-60
55. Robinson DM, Keating GM. Colesevelam: A review of its use in hypercholesterolemia. Am J Cardiovasc Drugs 2007;7:453-65
56. Henry RR, Aroda VR, Mudaliar S, et al. Effects of Colesevelam on Glucose Absorption and Hepatic/Peripheral Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus. Diabetes Obes Metab 2012;14:40-6
57. Schwartz SL, Lai YL, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: A pilot study. Metab Syndr Relat Disord 2010;8:179-88
58. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nihon Med Sch 2007;74:338-43
59. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide- 1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005;329:386-90
60. Chen L, McNulty J, Anderson D, et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 2010;334:164-70
61. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009;8:369-85
62. Hofmann AF. Bile acid sequestrants improve glycemic control in type 2 diabetes: A proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 2011;53:1784
63. Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: Targeting the bile acid pathway. Curr Opin Cardiol 2008;23:502-11
64. Patti M-E, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: Potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009;17:1671-7
65. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331:1621-4
66. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-603
67. Li T, Owsley E, Matozel M, et al. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010;52:678-90
68. Li T, Francl JM, Boehme S, et al. Glucose and insulin induction of bile acid synthesis: Mechanisms and implications in diabetes and obesity. J Biol Chem 2012;287:1861-73
69. Garg SK, Ritchie PJ, Moser EG, et al. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: A pilot randomized double-blind trial. Diabetes Obes Metab 2011;13:137-43
70. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: A randomized, prospective study. Endocr Pract 2010;16:617-28
71. Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol 2011;108:1129-35
72. Rosenstock J, Fonseca VA, Garvey WT, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 2010;16:629-40